It is the first multicenter pilot study proposing a therapeutic strategy based on biomarkers in patients with recurrent/metastatic HNSCC, palbociclib is indicated in patients with cyclin D1 (CCND1) amplification and p16 negativity [147]. The gene discussed is CCND1; the disease is head and neck squamous cell carcinoma.